The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

Eli Lilly said on Thursday its experimental obesity drug helped patients reduce 26.6% of weight, on average, across two late-stage studies after intensive lifestyle changes or with continued ...

New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and Ozempic for weight loss and lowering blood sugar.

Eli Lilly's anti-obesity drug Zepbound (tirzepatide) receives approval in the US and recommended approval in the EU. The SELECT study data shows that semaglutide 2.4 mg reduces major adverse ...

Chugai Pharmaceutical Co. Ltd. (OTC:CHGCY) believes its anti-muscle-wasting drug could be used alongside Eli Lilly And Co.’s (NYSE:LLY) oral obesity pill, orforglipron. Roche Holdings AG (OTC ...

Just two days after Novo Nordisk launched Wegovy (semaglutide 2.4 mg) in India, Eli Lilly received regulatory approval for the KwikPen® format of its rival therapy Mounjaro (tirzepatide) ...

Eli Lilly releases data for a new weight-loss drug to tackle obesity : Shots - Health News There's already a huge demand for existing weight-loss drugs, so the new medication is highly anticipated ...

The Food and Drug Administration on Wednesday approved Eli Lilly’s diabetes drug for treating obesity, opening the door for widespread insurance coverage that could make the sought-after ...

Eli Lilly started a new online service offering telehealth prescriptions and direct home delivery of its new anti-obesity drug Zepbound, an unusual move into the drug supply chain by a ...

Eli Lilly's experimental obesity drug, eloralintide, helped some patients lose 11.5% of their body weight at 12 weeks in an early-stage study, an investor note by brokerage Cantor Fitzgerald ...

Pharmaceutical giant Eli Lilly and Company is trying to clear up misconceptions about obesity care as it increases investment in its highly popular weight-loss drugs. With the latest phase of ...